Bristol Myers builds the case for psoriasis hopeful as it waits in regulatory limbo

Bristol Myers Squibb continues to tout more data for its experimental psoriasis drug that it hopes will shake up the market.

The pharmaceutical giant posted two-year results from a long-term extension study of deucravacitinib, showing the drug remained effective after two years. The drug, which analysts predict can bring in...

Click to view original post